Adient Reports $3.7B in Net Sales

By Philip Seaworth • Wednesday, August 06 10:20 • Permanent Link

Adient plc has reported its financial results for the three months ended June 30, 2025. The company's net sales for this period were $3,741 million, slightly up from the $3,716 million reported for the same period in 2024. The gross profit for the company also increased to $237 million from $207 million in 2024.

In terms of segment results, the Americas segment saw an increase in adjusted EBITDA margin from 5.7% in 2024 to 6.4% in 2025. Similarly, the EMEA segment's adjusted EBITDA margin increased from 1.9% in 2024 to 1.7% in 2025. The Asia segment also experienced growth, with its adjusted EBITDA margin rising from 14.2% in 2024 to 15.7% in 2025.

Adient's operating cash flow for the three months ended June 30, 2025, was $172 million, up from $158 million in the same period in 2024. The company's free cash flow also increased to $115 million in 2025 from $88 million in 2024.

The adjusted net income attributable to Adient for the period was $38 million, an improvement from $29 million in 2024. This translated to an adjusted diluted earnings per share of $0.45, up from $0.32 in 2024.

Adient's net debt as of June 30, 2025, was $1,534 million, compared to $1,460 million as of September 30, 2024. The net leverage ratio was 1.72 in 2025, slightly higher than the ratio of 1.66 in 2024.

Following these announcements, the company's shares moved 1.84%, and are now trading at a price of $22.11. If you want to know more, read the company's complete 8-K report here.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.